NCT01632423

A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 10,337 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

Conditions

• Glaucoma, Open-Angle
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	bimatoprost 0.01%	Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry

Timeline

• Start date: 2010-02-01
• Primary completion: 2010-11-01
• Completion: 2010-11-01
• First posted: 2012-07-03
• Last updated: 2012-09-21
• Results posted: 2012-09-21

Locations

1 site across 1 country: Germany